ArticleEuroasian journal of hepato-gastroenterology
A Prospective, Observational Study Evaluating the Incidence of Metallic Taste, Compliance, and Clinical Outcomes with Metronidazole Extended-release 600 mg Compared to Immediate-release Formulations (MERIT STUDY).
Article in Euroasian journal of hepato-gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metronidazole remains a cornerstone in the management of anaerobic bacterial and protozoal infections. However, its clinical utility is often limited by adverse effects such as a metallic taste (dysgeusia), which can negatively impact treatment adherence. Extended-release (ER) formulations have been developed to optimize pharmacokinetic profiles and improve tolerability. Objective: To evaluate the incidence of metallic taste, patient compliance, clinical outcomes, and safety of metronidazole ER 600 mg compared with immediate-release (IR) formulations. Materials and methods: This prospective, observational, multi-center study included 200 adult patients who were prescribed either metronidazole ER 600 mg ( Results: The incidence of metallic taste was significantly lower in the ER group compared to the IR group (8.82 vs 19.39%; Conclusion: Metronidazole ER 600 mg significantly improved tolerability and adherence while maintaining comparable efficacy and safety. It offers a clinically meaningful advantage in enhancing patient compliance for the treatment of anaerobic infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.